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Abstract 
 
Objectives To determine whether fetal overgrowth preceded the diagnosis of GDM, 
and to quantify the inter-relationships between fetal overgrowth, GDM and maternal 
obesity. 
Research Design and Methods We conducted a prospective cohort study of 
unselected nulliparous women, and performed ultrasonic measurement of the fetal 
abdominal circumference (AC) and head circumference (HC) at 20 and 28 wkGA. 
Exposures were diagnosis of GDM ≥28 wkGA and maternal obesity. The risk of AC 
>90th and HC:AC ratio <10th percentile were modelled using log-binomial regression, 
adjusted for maternal characteristics.  
Results 171 (4.2%) of 4069 women were diagnosed with GDM at ≥28 wkGA. There 
was no association between fetal biometry at 20 wkGA and subsequent maternal 
diagnosis of GDM. However, at 28 wkGA, there was an increased risk (adjusted 
relative risk [95% CI]) of AC >90th percentile (2.05 [1.37 to 3.07]) and HC:AC ratio 
<10th percentile (1.97 [1.30 to 2.99]). Maternal obesity showed similar associations at 
28 wkGA (2.04 [1.62 to 2.56] and 1.46 [1.12 to 1.90], respectively). The combination 
of GDM and obesity was associated with ~5-fold risk of AC >90th (4.52 [2.98 to 6.85]) 
and a ~3-fold risk of HC:AC ratio <10th percentile (2.80 [1.64 to 4.78]) at 28 wkGA. 
Fetal AC >90th percentile at 28 weeks was associated with ~4-fold risk of being large 
for gestational age at birth. 
Conclusions Diagnosis of GDM is preceded by excessive growth of the fetal AC 
between 20 and 28 wkGA, and its effects on fetal growth are additive with the effects 
of maternal obesity.  
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Gestational diabetes mellitus (GDM) is one of the most common acquired medical 
disorders of pregnancy1 and the major complication of GDM is excessive fetal 
growth. Low and middle income countries have a similar prevalence of GDM 
compared to high income countries, although the prevalence is particularly high in 
Vietnam, India, Bangladesh and Sri Lanka.2 Pregnancies affected by GDM carry an 
increased risk of adverse outcome for the mother and the offspring in the short 
term1;3;4 and the offspring are at increased risk of childhood obesity in the long term.4 
Large scale randomized controlled trials have confirmed that screening and 
treatment for GDM is associated with improved short term outcomes5;6 but have 
failed to show reduced rates of childhood obesity.7;8 Current guidelines recommend 
screening women for GDM between 24 to 28 weeks of gestational age (wkGA).1;3 In 
practice, many units screen at around 28 wkGA. The aims of the present analysis 
were (1) to determine whether the onset of fetal over-growth among women 
subsequently diagnosed with GDM preceded the normal time of screening for the 
condition, and (2) to determine the inter-relationships between fetal over-growth, 
GDM and maternal obesity. 
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Methods 
 
Design 
The Pregnancy Outcome Prediction study was conducted at the Rosie Hospital, 
Cambridge (UK) and has been previously described in detail.9;10 In brief, it was a 
prospective cohort study of nulliparous women with a viable singleton pregnancy 
who attended the hospital for their dating ultrasound scan between 14/08/2008 and 
31/07/2012. Blood was obtained at the time of recruitment. Further participation in 
the study involved attending the NIHR Cambridge Clinical Research Facility at ~20, 
~28 and ~36 wkGA for blood sampling and performance of ultrasound scans. 
Outcome data were obtained by review of each woman's paper case record by 
research midwives and by linkage to the hospital's electronic databases. Ethical 
approval for the study was given by the Cambridgeshire 2 Research Ethics 
Committee (reference number 07/H0308/163) and all participants provided written 
informed consent. The reporting of this study conforms to the STROBE (The 
Strengthening the Reporting of Observational Studies in Epidemiology) statement. 
 
Analysis of fetal growth 
The conduct and descriptive data of the research ultrasounds are described in detail 
elsewhere.9;10 In brief, gestational dating was performed using ultrasound, and 
99.5% of these examinations were performed prior to 15 wkGA. The current analysis 
focuses on the results of fetal biometry at 20 and 28 wkGA. All scans were 
performed on a Voluson i (GE, Fairfield CT, USA). The data from the 20 wkGA scan 
were from the routine anomaly scan offered to all women, and these results were 
revealed to the women and clinical team. The data from the 28 wkGA scan were 
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fetal biometry performed for the purposes of research, and these results were 
blinded. The fetal head circumference (HC) and abdominal circumference (AC) were 
measured using the ellipse function on the machine at the standard anatomical 
sites.11 We have previously shown that these measurements have low inter-observer 
variability.10 To allow for minor variations in the exact timing of the 20 and 28 wkGA 
ultrasound scans, all fetal biometry was expressed as gestational age adjusted 
standard deviation scores (z scores), using the distribution of the measurements 
within the dataset.10 The AC growth velocity was quantified as the difference 
between the AC z score at 28 wkGA and the AC z score at 20 wkGA. This approach 
accounts for nonlinear changes and the increasing variability of biometric 
measurements by gestational age, and makes different measurements from different 
gestational ages comparable.12 13 Z scores for HC, AC and AC growth velocity were 
categorised into deciles, using the distribution within the study cohort. The highest 
decile of AC and AC growth velocity and the lowest decile of HC:AC ratio were 
defined as abnormal. Sex and gestational age corrected birth weight percentiles and 
z scores were calculated using a population-based UK reference.14 
 
Definitions 
Maternal age was defined as age at recruitment. Body mass index (BMI) was 
calculated using each woman's measured height and their measured weight on the 
day of their booking scan. Maternal obesity was defined as BMI ≥30kg/m2. Maternal 
weight gain was defined as the difference in measured weight at the time of the 28 
wkGA scan and the booking scan. Maternal ethnicity was defined by self-report in a 
questionnaire administered at the 20 wkGA scan. Large for gestational age (LGA) 
was defined as a sex and gestational age specific birth weight percentile >90th. 
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Screening and diagnosis of GDM 
All pregnant women were offered screening at the first antenatal booking visit with a 
random plasma glucose. Women with random glucose >7.0mmol/l (>126mg/dl) were 
offered a 75g oral glucose tolerance test (OGTT). Women were screened again at 
~28 wkGA, firstly with a 50g glucose challenge test (GCT), followed by a 75g OGTT 
if the GCT was >7.7mmol/l (>139mg/dl), as previously described.15 Screening for 
GDM was usually performed on the same day as the 28 week ultrasound scan, and 
GDM diagnosis was made shortly after that. Uptake of the GCT was >85% (the exact 
proportion could not be calculated as some tests took place in primary care). 
Between 2008 and 2010, GDM diagnosis was based on diagnostic criteria adapted 
from the WHO (1999) recommendations: fasting, 1-hour and 2-hour glucose levels 
greater than 6.1 (110 mg/dl), 10.0 (180 mg/dl) or 7.8 mmol/l (140 mg/dl), 
respectively. From 2011 onwards, these were replaced with diagnostic criteria 
adapted from the International Association of Diabetes and Pregnancy Study 
Groups' recommendations: fasting, 1-hour and 2-hour glucose levels greater than 
5.3 (95 mg/dl), 10.0 (180 mg/dl) or 8.5 mmol/l (153 mg/dl), respectively.16 Information 
on the subsequent treatment of GDM was obtained by individual review of each 
patient's clinical case record. Treatment was generally informed and monitored by 
home testing using a glucometer, with fasting and 1-hour post-prandial 
measurements made four times per day. All women diagnosed with GDM were 
offered a post-partum 2 hour, 75g fasting OGTT to exclude any ongoing glycaemic 
dysregulation (impaired fasting hyperglycaemia, impaired glucose tolerance or type 2 
diabetes mellitus). This allowed us to identify women who also had abnormal 
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glucose tolerance outside pregnancy and, therefore, had non-gestational glycaemic 
dysregulation. 
 
Exclusion criteria 
We excluded women who withdrew from the study, who were lost to follow-up, who 
failed to attend the 20 or 28 wkGA scan, who had pre-existing diabetes or had GDM 
diagnosed prior to 28 wkGA, or had missing data on GDM or BMI. The women with 
GDM who could not be confirmed to have a normal post-partum OGTT were 
included in the main analysis and the effect of excluding them was assessed in a 
sensitivity analysis. 
 
Statistical Analysis 
Numerical data were compared using a two-sample Wilcoxon rank-sum test, and 
categorical data were compared using a Pearson Chi-square test with test for trend, 
as appropriate. The associations between the combination of GDM and obesity and 
the indicators of abnormal fetal growth were modelled using log-binomial regression 
to obtain adjusted relative risks. The relative risk of AC in the top decile at 28wkGA 
associated with subsequent GDM was estimated in the whole study group and 
stratified by maternal obesity, the treatment used, the diagnostic criteria employed, 
and confined to women with a normal post-partum OGTT. Non-linearity was 
assessed using fractional polynomials and interactions were tested using the 
likelihood ratio test. Missing covariate data were imputed using chained equations.17 
All analyses were adjusted for the year of the 28 wkGA scan to take into account any 
temporal changes in the incidence, screening, diagnosis or treatment of GDM. 
Analyses were performed with and without adjustment for maternal age, height, 
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ethnicity, weight gain and BMI, as appropriate. Finally, the relative risk of LGA at 
birth associated with the indicators of abnormal fetal growth was estimated in the 
group of women who were obese and/or had GDM diagnosed at ≥28 wkGA. All 
analyses used Stata version 14.0.   
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Results 
 
Among 4,512 recruited women, a total of 4,305 attended for their 28 wkGA scan (see 
Sovio et al,10 for flow diagram). Of these, 7 withdrew, 6 failed to attend their 20 wkGA 
scan, 188 delivered elsewhere, 14 women had pre-existing diabetes, 17 women had 
GDM diagnosed prior to 28 wkGA and 7 women had missing data on GDM or BMI. A 
total of 236 (5.5%) of these women had one or more of the exclusion criteria, leaving 
a study group of 4,069 among whom 171 (4.2%) had a diagnosis of GDM ≥28 wkGA. 
Women who subsequently developed GDM were older, shorter, more likely to be 
obese, gained slightly less weight, and were more likely to have induced labour and 
caesarean delivery (Table 1). Their babies were born slightly smaller, but had higher 
birth weight z scores and a higher proportion of them were LGA. 
 
At 20 wkGA, there were no significant differences in fetal biometry associated with 
subsequent GDM, however, the risks of AC >90th and HC:AC ratio <10th percentile 
were increased in fetuses of obese mothers (Table 2). At 28 wkGA, subsequent 
GDM and maternal obesity were each associated with an approximate 2-fold risk of 
AC >90th and a 1.5 to 2-fold risk of HC:AC ratio <10th percentile. The effects of 
obesity and subsequent GDM were additive: the combination was associated with an 
almost 5-fold risk of AC >90th and an almost 3-fold risk of HC:AC ratio <10th 
percentile at 28 wkGA. Subsequent GDM and maternal obesity were each 
associated with an increased risk of AC growth velocity >90th percentile, and the 
combination was associated with an almost 3-fold risk. 
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There were no interactions between the two exposures, or between either exposure 
and any of the maternal covariates in their associations with fetal biometry (all 
P>0.05). Of the 171 women with GDM, 123 (72%) attended for a post-partum 75g 
fasting OGTT, and 116 of them had a normal result (fasting glucose <6.1 [110 mg/dl] 
and a 2 hour glucose <7.8 mmol/l [140 mg/dl]). The proportion of AC >90th percentile 
in the 116 women who had a normal post-partum OGTT was similar to the 55 
women who could not be confirmed to have a normal post-partum OGTT (19.8% 
versus 25.5%, P=0.4). The relative risk of AC >90th percentile associated with 
subsequent GDM was similar when stratified by maternal obesity, the treatment 
used, the diagnostic criteria employed, and when the analysis was confined to 
women with a normal post-partum OGTT (Figure 1). Of the 4,069 women in the 
cohort, 749 (18.4%) had complete data on the result of the 75g fasting OGTT. 194 
(4.8%) of the 4,069 women were deemed screen positive using the modified WHO 
(1999) criteria whereas 142 (3.5%) screened positive using the modified IADPSG 
criteria. There were 54 (1.3%) women who were screen positive using the modified 
WHO criteria but not the modified IADPSG criteria and two (<0.1%) women who 
were screen positive using the modified IADPSG criteria but not the modified WHO 
criteria. 
 
Ultrasonic fetal biometry at 28 weeks identified pregnancies at increased risk of an 
LGA infant at delivery among the 672 women who were obese and/or had a 
diagnosis of GDM ≥28 weeks. AC growth velocity >90th percentile was associated 
with a 2-fold risk (adjusted relative risk [95% CI]) of LGA (1.87 [1.05 to 3.35]) and AC 
>90th percentile were associated with a 4-fold risk of LGA (3.86 [2.37 to 6.29]). 
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Discussion 
 
We found that excessive fetal growth preceded clinical diagnosis of GDM. At 28 
wkGA, the risks of AC >90th and HC:AC ratio <10th percentile were doubled. No 
differences were apparent at the time of the 20 wkGA scan. Moreover, fetuses of 
women who were subsequently diagnosed with GDM had increased growth velocity 
of the AC between 20 and 28 wkGA. These data suggest that the onset of fetal 
growth disorder in GDM predates the usual time of screening. The current 
observations cannot be explained by misclassification of non-gestational glycaemic 
dysregulation as GDM, because the results were very similar when confined to 
women with confirmed normal postpartum glucose tolerance. A slightly different 
pattern was observed for maternal obesity, as the fetuses of obese women already 
demonstrated increased risks of AC >90th and HC:AC ratio <10th percentile at 20 
wkGA. However, obesity was also associated with accelerated growth between 20 
and 28 wkGA. Moreover, the effects of obesity and GDM on fetal growth were 
additive. Consequently, at 28 wkGA, the fetuses of obese women who had a 
subsequent diagnosis of GDM had an almost 5-fold risk of AC >90th and an almost 3-
fold risk of HC:AC ratio <10th percentile. Finally, among the population of women with 
obesity and/or GDM, fetal AC >90th at 28 weeks and increased fetal AC growth 
velocity  between 20 and 28 weeks were associated with an increased risk of 
macrosomia at delivery. 
 
The U.S. Preventive Services Task Force and the American College of Obstetricians 
& Gynecologists in the US,1;3 and the National Institute for Health and Care 
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Excellence in the UK,18 all recommend that biochemical testing for GDM takes place 
between 24 and 28 wkGA. Practice differs internationally, and between units within 
countries, about whether biochemical screening is universal, using a 50g GCT, or 
targeted at high risk women using a 75g fasting OGTT. We use the former approach, 
as previously described.15 Whichever method is employed, units typically screen 
women at 28 wkGA. Our data suggest that fetal growth is already abnormal at 28 
wkGA in women subsequently diagnosed with GDM. Consequently, our data 
suggest that screening prior to 28 wkGA may be one approach to improving the 
short and long term outcomes of pregnancies complicated by GDM. The U.S. 
Preventive Services Task Force has previously observed that there is an absence of 
evidence regarding the effects of earlier screening.1 Such an approach may be 
particularly likely to improve outcomes among obese women, as fetal growth was 
already abnormal by 20 wkGA among these women in the cohort. In fact, the current 
data indicate that any intervention aimed at reducing the risk of LGA in the infants of 
obese women may need to be implemented before 20 wkGA. Finally, the offspring of 
women with GDM are at increased risk of childhood obesity4 but RCTs have failed to 
demonstrate that screening and intervention in pregnancy reduces this risk.7;8 The 
current data suggest a possible explanation, namely, that screening and intervention 
is taking place when the effects of GDM are already manifested in the fetus. Hence, 
the current findings indicate that earlier screening and intervention for GDM may 
result in better short and long term outcomes. Testing this hypothesis would be an 
appropriate focus for future randomised controlled trials. 
 
The main strengths of the current study are that it was prospective, and that 
ultrasonic fetal biometry was performed at 20 and 28 wkGA in a large cohort of 
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unselected nulliparous women. Many other studies of fetal growth in both pre-
existing and gestational diabetes are confined to women who had a diagnosis of 
diabetes.19;20 It is clearly problematic to define abnormal growth related to diabetes in 
the absence of data on fetal growth in non-diabetic women. Further strengths of the 
study are that we had detailed clinical information on the individual women. Hence, 
we were able to analyse the results in relation to the treatment used for GDM, and in 
relation to the results of re-testing of women in the post-partum period. Moreover, we 
had detailed information on maternal covariates, such as anthropometry, weight 
gain, ethnicity and age. The incidence of GDM in our cohort was consistent with UK 
rates of 3-5% when universal biochemical screening is performed.21 However, the 
women in the cohort were mostly of white European ancestry. We did not observe 
any statistically significant interactions between ethnicity and the exposures, 
however, the numbers were small. The present study recruited women over a 4.5 
year period. During this period of time, there were changes in the definition of GDM. 
In the study cohort, 4.8% of the women were deemed screen positive using the 
modified WHO (1999) criteria whereas 3.5% screened positive using the modified 
IADPSG criteria. There were 54 (1.3%) women who screened positive using the 
modified WHO (1999) criteria but not the modified IADPSG criteria and two (<0.1%) 
women who had the opposite discrepancy. However, the results were virtually 
identical when the association was studied by year of the 28 wkGA scan. The HAPO 
study22 demonstrated a continuum in the risk of LGA in relation to hyperglycaemia. 
The similar findings in relation to AC comparing the modified WHO and the modified 
IADPSG criteria may reflect the fact that women just below a given threshold are 
very similar to those who lie just above it. Finally, the use of the 50g GCT approach 
is estimated to have a sensitivity of 74% for GDM.23 It follows that some of the 
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women defined as normal in the cohort may have had undiagnosed GDM. 
Misclassification tends to lead to underestimates of the strength of true associations, 
and it is possible that the associations would have been even stronger had all 
women been screened using a fasting 75g OGTT. 
 
Conclusions 
Diagnosis of GDM ≥28 wkGA is preceded by excessive fetal growth between 20 and 
28 wkGA. Currently, biochemical testing for GDM typically takes place at around 28 
wkGA. As fetal growth is already abnormal at this stage, it is plausible that earlier 
screening and intervention may result in lower risks of adverse outcomes. 
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Table 1. Characteristics of the study population by gestational diabetes 
mellitus (GDM), n=4,069. 
 
Characteristic No GDM (n=3,898) GDM (n=171) P Value* 
     
Maternal characteristics 
Age, years 30 (27 to 33) 32 (28 to 35) <0.001 
 <20 145 (3.7) 2 (1.2)  
 
<0.001 
 20 to 24.9 524 (13) 17 (9.9) 
 25 to 29.9 1216 (31) 42 (25) 
 30 to 34.9 1445 (37) 64 (37) 
 35 to 39.9 502 (13) 37 (22) 
 ≥40 66 (1.7) 9 (5.3) 
     
Age stopped FTE, years 21 (18 to 23) 21 (18 to 23) 0.18 
 <19 1306 (34) 62 (36)  
0.37  19 to 22 1352 (35) 56 (33) 
 ≥23  1128 (29) 45 (26) 
 Missing 112 (2.9) 8 (4.7)  
     
Height, cm 165 (161 to 170) 164 (160 to 167) 0.001 
 <160 699 (18) 42 (25)  
0.003  160 to 164.9 1064 (27) 52 (30) 
 165 to 169.9 1157 (30) 48 (28) 
 ≥170  978 (25) 29 (17) 
     
BMI, kg/m2 24 (22 to 27) 26 (24 to 32) <0.001 
 <25 2324 (60) 56 (33)  
 
<0.001 
 25 to 29.9 1073 (28) 63 (37) 
 30 to 34.9 366 (9.4) 23 (13) 
 35 to 39.9 94 (2.4) 20 (12) 
 ≥40 41 (1.1) 9 (5.3) 
    
Weight gain from 12 to 28 
wkGA scan, kg† 
8 (6 to 10) 7 (5 to 10) 0.04 
    
Ethnicity    
 White 3625 (93) 154 (90)  
 
0.33 
 Indian/Pakistani/Bangladeshi 71 (1.8) 6 (3.5) 
 African Caribbean/African 22 (0.6) 0 (0.0) 
 Far/South East Asian 62 (1.6) 3 (1.8) 
 Other/Mixed 55 (1.4) 4 (2.3) 
 Missing 63 (1.6) 4 (2.3)  
    
Birth characteristics 
Birth weight, g 3425 (3110 to 3745) 3295 (3015 to 3550) <0.001 
Birth weight, z score -0.16 (-0.73 to 0.40) 0.04 (-0.45 to 0.60) <0.001 
Birth weight, centile    
 Small (<10th) 356 (9.1) 7 (4.1)  
0.004  Normal (10th-90th) 3367 (86) 151 (88) 
 Large (>90th) 174 (4.5) 13 (7.6) 
 Missing 1 (<0.1) 0 (0.0)  
    
Gestational age, 40.4 (39.3 to 41.1) 38.9 (38.3 to 39.6) <0.001 
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completed weeks 
 <37 158 (4.1) 7 (4.1)  
<0.001  37-38 550 (14) 81 (47) 
 39 787 (20) 54 (32) 
 40 1134 (29) 24 (14) 
 ≥41 1269 (33) 5 (2.9) 
     
Fetal sex    
 Male 1952 (50) 90 (53) 0.52 
 Female 1945 (50) 81 (47) 
 Missing 1 (<0.1) 0 (0.0)  
     
Induction of labour 1177 (30) 115 (67) <0.001 
     
Mode of delivery    
 Spontaneous vaginal 1927 (49) 61 (36)  
 
<0.001 
 Assisted vaginal 915 (23) 43 (25) 
 Intrapartum caesarean 674 (17) 33 (19) 
 Pre-labour caesarean 373 (9.6) 33 (19) 
 Missing 9 (0.2) 1 (0.6) 
     
Data are expressed as median (IQR) or n (%) as appropriate.  
*P-values are for difference between groups calculated using the two-sample 
Wilcoxon rank-sum (Mann-Whitney) test for continuous variables and the Pearson 
Chi-square test for categorical variables, with trend test as appropriate. The missing 
category was not included in statistical tests. 
†The difference in weight gain from 12 to 28 wkGA scan was tested additionally 
using linear regression. Without BMI adjustment, the difference in weight gain 
associated with GDM was -0.6 kg (95%CI: -1.1 to -0.1 kg, p=0.01) and after BMI 
adjustment it was -0.3 kg (95%CI: -0.8 to +0.2 kg, p=0.20). 
For fields where there is no category labelled "missing", data were 100% complete. 
FTE denotes full time education, BMI denotes body mass index. 
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Table 2. The association between gestational diabetes mellitus (GDM), obesity and fetal growth indicators. 
  Exposure: Obesity only 
RR (95% CI)* 
Exposure: GDM only 
RR (95% CI)* 
Exposure: GDM and obesity
RR (95% CI)* 
Growth outcomes† N Adjusted 
 for year 
Fully  
adjusted‡ 
Adjusted  
for year 
Fully  
adjusted‡ 
Adjusted  
for year 
Fully  
adjusted‡ 
AC at 20 wkGA 
>90th percentile 
 
4052 1.55 
 (1.23 to 1.96)
1.63 
 (1.29 to 2.06)
0.89 
 (0.49 to 1.63) 
0.93 
 (0.51 to 1.70)
1.82 
 (1.00 to 3.33)
2.01 
 (1.10 to 3.69)
HC:AC at 20 wkGA 
<10th percentile$ 
 
3994 1.78 
 (1.41 to 2.24)
1.80 
 (1.42 to 2.27)
1.05 
 (0.59 to 1.86) 
1.08 
 (0.61 to 1.93)
1.78 
 (0.93 to 3.39)
1.93 
 (1.01 to 3.70)
ACGV 20-28 wkGA  
>90th percentile 
 
4048 1.37 
 (1.06 to 1.77)
1.40 
 (1.08 to 1.81)
1.72 
 (1.12 to 2.64) 
1.77 
 (1.15 to 2.71)
2.55 
 (1.54 to 4.25)
2.78 
 (1.67 to 4.65)
AC at 28 wkGA 
>90th percentile 
 
4065 1.86 
 (1.48 to 2.34)
2.04  
(1.62 to 2.56) 
2.06  
(1.38 to 3.09) 
2.05  
(1.37 to 3.07) 
3.89 
 (2.54 to 5.95)
4.52  
(2.98 to 6.85) 
HC:AC at 28 wkGA  
<10th percentile$ 
 
3861 1.37 
 (1.05 to 1.78)
1.46 
 (1.12 to 1.90)
2.07 
 (1.37 to 3.14) 
1.97 
 (1.30 to 2.99)
2.64 
 (1.54 to 4.50)
2.80 
 (1.64 to 4.78)
*Associations were expressed as relative risks (RR) with 95% confidence intervals (CI), referent to non-obese women with no diagnosis of 
GDM.  
†Growth outcomes were dichotomized as >90th percentile (AC and ACGV) or <10th percentile (HC:AC).The z score cut-off points were 1.2721 
for AC at 20 wkGA, -1.2320 for HC:AC at 20 wkGA, 1.2851 for ACGV 20-28 wkGA, 1.2851 for AC at 28 wkGA and -1.2373 for HC:AC at 28 
wkGA. The mean (SD) gestational age of the scans were 20.4 (0.5) and 28.3 (0.4) wkGA. 
‡Adjusted for the year of the 28 wkGA scan, maternal age, height, ethnicity (Indian/Pakistani/Bangladeshi vs. others) and weight gain (all 
maternal characteristics listed in Table 1 were considered as potential confounders). Multiple imputation was performed using chained 
equations (m=10 imputations). Predictive mean matching (k=10 donors) and logistic regression were employed in the imputation of weight gain 
and ethnicity, respectively. To improve the imputation accuracy of the covariates, exposures and outcomes were also included in the imputation 
model, along with age when the woman stopped full time education since this variable was associated with weight gain and ethnicity. 
$Significantly reduced HC:AC ratios were not due to smaller HC. 
AC denotes abdominal circumference, GV denotes growth velocity, HC denotes head circumference and wkGA denotes weeks of gestational 
age. 
The sample size in the different analyses varies between 3,861 and 4,065, principally due to missing values in biometric head measurements, 
which are dependent on fetal position.
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Figure legend 
 
Figure 1. Stratified analysis of the association between gestational diabetes 
mellitus (GDM) and abdominal circumference (AC) >90th percentile at 28 wkGA.  
Points are adjusted relative risks and bars are 95% CI. Stratification was by obesity 
(BMI≥30kg/m2), GDM treatment type (diet only or medication [insulin or metformin]) 
and year of the 28 wkGA scan (2008-2010 diagnoses were based on a modified 
version of the 1999 WHO criteria: fasting, 1-hour and 2-hour glucose levels greater 
than 6.1 [110 mg/dl], 10.0 [180 mg/dl] or 7.8 mmol/l [140 mg/dl], respectively, and 
2011-2012 diagnoses were based on the modified IADPSG criteria: thresholds 5.3 
[95 mg/dl], 10.0 [180 mg/dl] or 8.5 mmol/l [153 mg/dl], respectively). 116 women had 
a diagnosis of GDM in the pregnancy, attended for a 75g fasting OGTT at ~6 weeks 
postpartum, and had a normal result (fasting glucose <6.1 [110 mg/dl] and a 2 hour 
glucose <7.8 mmol/l [140 mg/dl]). Analyses were adjusted for the year of the 28 
wkGA scan, maternal age, height, ethnicity (Indian/Pakistani/Bangladeshi vs. 
others), weight gain and BMI, as appropriate (where the analysis was not stratified 
by the respective variable). 
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